Bladder Cancer, Renal Cancer
Conditions
Keywords
Bladder Cancer, Renal Cancer, CIK
Brief summary
Treatment of metastatic tumors of the urogenital area with cytokine-induced killer cells
Detailed description
Treatment of metastatic tumors of the urogenital area using autologous cytokine-induced killer cells
Interventions
BIOLOGICALcytokine-induced killer cells
Autologous cytokine-induced killer cells injected intravenously
Standard treatment of bladder/renal cancer according to the Clinical protocols
Sponsors
Belarusian State Medical University
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed diagnosis of pTa metastatic tumors of the urogenital area; * Patient who require repetitive transurethral resection; * Expression of muc-1/wt-1 by the tumor; * EGOC 0-3;
Exclusion criteria
* any medical condition which can be associated with the high risk for the patient; * pregnancy/lactation; * chronic infections, including hepatitis B/C, tuberculosis, HIV
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The relapse-free survival | 1 year | The duration of relapse-free survival |
| Adverse effects associated with the therapy | 1 month | Determination of adverse effects associated with the therapy |
Countries
Belarus
Contacts
Primary ContactAndrei Hancharou, Dr
Backup ContactOksana Timohina
Outcome results
None listed